Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica

Angel T. Alvarado; Juan Cotuá; Maryori Delgado; Alexis Morales; Ana María Muñoz; César Li Amenero; María R. Bendezú; Jorge A. García; Doris Laos-Anchante; Felipe Surco-Laos; Berta Loja; Mario Bolarte-Arteaga; Mario Pineda-Pérez

doi:10.56499/jppres22.1500_10.6.1117

Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica

Translated title of the contribution: Serum concentrations of valproic acid in people with epilepsy: Clinical implication

Angel T. Alvarado, Juan Cotuá, Maryori Delgado, Alexis Morales, Ana María Muñoz, César Li Amenero, María R. Bendezú, Jorge A. García, Doris Laos-Anchante, Felipe Surco-Laos, Berta Loja, Mario Bolarte-Arteaga, Mario Pineda-Pérez

FARMACIA Y BIOQUIMICA

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R² = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

Translated title of the contribution	Serum concentrations of valproic acid in people with epilepsy: Clinical implication
Original language	Spanish
Pages (from-to)	1117-1125
Number of pages	9
Journal	Journal of Pharmacy and Pharmacognosy Research
Volume	10
Issue number	6
DOIs	https://doi.org/10.56499/jppres22.1500_10.6.1117
State	Published - Nov 2022

Bibliographical note

Funding Information:
The authors thank the members of the Molecular Pharmacology Society of Peru for their participation in this study. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Publisher Copyright:
© 2022 Journal of Pharmacy & Pharmacognosy Research.

Access to Document

10.56499/jppres22.1500_10.6.1117

Cite this

Alvarado, A. T., Cotuá, J., Delgado, M., Morales, A., Muñoz, A. M., Amenero, C. L., Bendezú, M. R., García, J. A., Laos-Anchante, D., Surco-Laos, F., Loja, B., Bolarte-Arteaga, M., & Pineda-Pérez, M. (2022). Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica. Journal of Pharmacy and Pharmacognosy Research, 10(6), 1117-1125. https://doi.org/10.56499/jppres22.1500_10.6.1117

@article{8da9329633a24f6cbf8586e25c108b47,

title = "Concentraciones s{\'e}ricas de {\'a}cido valproico en personas con epilepsia: Implicaci{\'o}n cl{\'i}nica",

abstract = "Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.",

keywords = "dose-dose relationship, epilepsy, serum concentration, therapeutic monitoring, valproic acid",

author = "Alvarado, {Angel T.} and Juan Cotu{\'a} and Maryori Delgado and Alexis Morales and Mu{\~n}oz, {Ana Mar{\'i}a} and Amenero, {C{\'e}sar Li} and Bendez{\'u}, {Mar{\'i}a R.} and Garc{\'i}a, {Jorge A.} and Doris Laos-Anchante and Felipe Surco-Laos and Berta Loja and Mario Bolarte-Arteaga and Mario Pineda-P{\'e}rez",

note = "Publisher Copyright: {\textcopyright} 2022 Journal of Pharmacy & Pharmacognosy Research.",

year = "2022",

month = nov,

doi = "10.56499/jppres22.1500_10.6.1117",

language = "Espa{\~n}ol",

volume = "10",

pages = "1117--1125",

journal = "Journal of Pharmacy and Pharmacognosy Research",

issn = "0719-4250",

publisher = "Asociacion Academica de Ciencias Farmaceuticas de Antofagasta (ASOCIFA)",

number = "6",

}

Alvarado, AT, Cotuá, J, Delgado, M, Morales, A, Muñoz, AM, Amenero, CL, Bendezú, MR, García, JA, Laos-Anchante, D, Surco-Laos, F, Loja, B, Bolarte-Arteaga, M & Pineda-Pérez, M 2022, 'Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica', Journal of Pharmacy and Pharmacognosy Research, vol. 10, no. 6, pp. 1117-1125. https://doi.org/10.56499/jppres22.1500_10.6.1117

TY - JOUR

T1 - Concentraciones séricas de ácido valproico en personas con epilepsia

T2 - Implicación clínica

AU - Alvarado, Angel T.

AU - Cotuá, Juan

AU - Delgado, Maryori

AU - Morales, Alexis

AU - Muñoz, Ana María

AU - Amenero, César Li

AU - Bendezú, María R.

AU - García, Jorge A.

AU - Laos-Anchante, Doris

AU - Surco-Laos, Felipe

AU - Loja, Berta

AU - Bolarte-Arteaga, Mario

AU - Pineda-Pérez, Mario

PY - 2022/11

Y1 - 2022/11

N2 - Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

AB - Context: Therapeutic drug monitoring (TDM) allows personalizing the dose of valproic acid in patients with epilepsy to optimize drug therapy, minimize adverse effects and detect interactions. Aims: To determine valproic acid concentrations in serum samples from people with epilepsy and to analyze its clinical implications. Methods: Cloned donor enzyme immunoassay; descriptive, cross-sectional, non-randomized, convenience recruitment study of 57 voluntary patients with epilepsy (n = 39 male, 68.42%; n = 18 female, 31.58%) aged between 19 and 62 years. After three months of treatment with valproic acid, a single blood sample was collected from each volunteer at a minimal concentration. Results: Serum drug concentrations 51.30-100.10 mg/L (SD 5.94) and level/dose 2.17-5.31 (SD 1.14) were observed. Association was shown between the dose ratio/dose of valproic acid (R2 = 0.8693; p<0.05) and the Mann-Whitney U test (p<0.05). Valproic acid monotherapy and association with carbamazepine and phenytoin are not different between treatment groups (Mann-Whitney U test: p = 0.391 > α = 0.05). Conclusions: Serum valproic acid concentrations are within the therapeutic range, and there is a significant inverse linear correlation between dose ratio/dose, which must be considered to personalize the dose and optimize the pharmacotherapeutic result.

KW - dose-dose relationship

KW - epilepsy

KW - serum concentration

KW - therapeutic monitoring

KW - valproic acid

UR - http://www.scopus.com/inward/record.url?scp=85144217415&partnerID=8YFLogxK

U2 - 10.56499/jppres22.1500_10.6.1117

DO - 10.56499/jppres22.1500_10.6.1117

M3 - Artículo

AN - SCOPUS:85144217415

SN - 0719-4250

VL - 10

SP - 1117

EP - 1125

JO - Journal of Pharmacy and Pharmacognosy Research

JF - Journal of Pharmacy and Pharmacognosy Research

IS - 6

ER -

Concentraciones séricas de ácido valproico en personas con epilepsia: Implicación clínica

Abstract

Bibliographical note

Access to Document

Fingerprint

Cite this